PMID: 9169300May 1, 1997Paper

Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial

European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
C M BeasleyJ N Beuzen

Abstract

A 6-week acute phase of an international 1-year double-blind study was conducted comparing three dose ranges of olanzapine (5 +/- 2.5 mg/day, 10 +/- 2.5 mg/day, and 15 +/- 2.5 mg/day) with a fixed dose of olanzapine (1.0 mg/day) and with a dose range of haloperidol (15 +/- 5 mg/day) in the treatment of 431 patients with schizophrenia. The purpose was to determine whether olanzapine demonstrated a dose-related ability to decrease overall psychopathology with minimal associated extrapyramidal symptoms in patients with schizophrenia. The high-dose olanzapine group showed statistically significantly greater improvement in overall psychopathology based on mean change in the CGI Severity score and statistically significantly greater improvement in positive psychotic symptoms based on mean change in both the BPRS positive score and the PANSS positive score compared with the 1.0-mg/day olanzapine group. Analyses indicated that an increasing dose-response curve was observed across the range of all olanzapine dose groups. Acute extrapyramidal syndromes were reported less frequently among all olanzapine groups compared with the haloperidol group. Endpoint mean change on both the Simpson-Angus Scale and the Barnes Akathisia Scale reflected...Continue Reading

Associated Clinical Trials

Jul 13, 2006·David C. Henderson, MD, David C. Henderson, MD

References

Jan 31, 1977·Psychopharmacology·H Y MeltzerV S Fang
May 1, 1989·The British Journal of Psychiatry : the Journal of Mental Science·T R Barnes
Jan 1, 1989·Psychopharmacology·D E Casey
Jan 1, 1989·Psychopharmacology·M LeppigH Hippius
Jan 1, 1989·Psychopharmacology·H J GaertnerJ Hoss
Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Jan 1, 1970·Acta Psychiatrica Scandinavica. Supplementum·G M Simpson, J W Angus
Jan 1, 1981·Psychopharmacology·J M KaneS Bailine
Jul 15, 1993·The New England Journal of Medicine·J M AlvirJ A Schaaf
Feb 1, 1996·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·M E Stockton, K Rasmussen
Mar 1, 1996·Psychopharmacology·C M BeasleyS Hamilton

❮ Previous
Next ❯

Citations

Mar 20, 2004·Irish Journal of Medical Science·J V Lucey, S E Libretto
Dec 10, 2003·Archives of Pharmacal Research·Josephine S Modica-NapolitanoJune R Aprille
Oct 18, 2005·Pharmacy World & Science : PWS·I SchillevoortH G M Leufkens
Feb 26, 2013·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·S LeuchtR R Engel
Jan 31, 2002·Progress in Neuro-psychopharmacology & Biological Psychiatry·Gurpreet Kaur, Shrinivas K Kulkarni
Apr 15, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Julio BobesMiguel Gutiérrez
Dec 31, 2002·Psychoneuroendocrinology·R Tandon, M D Jibson
Aug 10, 2001·Journal of Pain and Symptom Management·R S KiserP N Fuchs
Jun 5, 2003·Journal of Pain and Symptom Management·Manish SrivastavaRuth Lagman
Oct 25, 2001·Journal of Clinical Epidemiology·J A SacristánP Kind
Aug 2, 2001·Schizophrenia Research·T H McGlashan
Apr 22, 2004·Schizophrenia Research·Jean-Pierre LindenmayerVirginia L Stauffer
Aug 21, 2003·European Psychiatry : the Journal of the Association of European Psychiatrists·Ann M Mortimer
Oct 6, 2001·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·S KasperA Heiden
Jun 17, 2003·Journal of the American Medical Directors Association·Richard J Goldberg
Jun 17, 2003·Journal of the American Medical Directors Association·Richard J Goldberg
Jul 11, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Stefan LeuchtRolf R Engel
Aug 15, 2006·Schizophrenia Bulletin·Stefan LeuchtJohn M Davis
Apr 3, 2003·Clinical Neuropharmacology·Vladimir Lerner
Mar 17, 2001·International Clinical Psychopharmacology·J Kane
Jul 19, 2001·International Clinical Psychopharmacology·S KasperUNKNOWN RODOS Investigator Group
Jul 19, 2001·International Clinical Psychopharmacology·S KasperUNKNOWN RODOS Investigator Group
Nov 1, 2002·International Clinical Psychopharmacology·J L CarrascoJ Gibert
Aug 28, 2012·The Journal of Nervous and Mental Disease·Neil Krishan AggarwalRobert A Rosenheck
Mar 11, 2004·Psychiatry and Clinical Neurosciences·Won-Myong BahkKwang-Soo Kim
Aug 12, 1999·Acta Psychiatrica Scandinavica·T Baptista
Jan 9, 2008·BMC Psychiatry·Ilya LipkovichJohn P Houston
May 11, 2011·PloS One·Toshi A Furukawa, Stefan Leucht
Jul 23, 1999·Pharmacotherapy·Y C ChanG Neufeld
Jun 30, 2004·CNS Drugs·Bruce J KinonPeter F Buckley
Jan 25, 2011·CNS Drugs·John KasckowSidney Zisook
Mar 19, 2009·The Indian Journal of Medical Research·Rajesh Jaco
Oct 27, 2011·Aging Health·John KasckowSidney Zisook
Feb 5, 2014·Schizophrenia Bulletin·Stefan LeuchtJohn M Davis
Nov 23, 2013·Schizophrenia Research·Myrto T SamaraStefan Leucht

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.